Early trial tests vaccine to train body to fight breast cancer
NCT ID NCT04144023
Summary
This early-stage study is testing a vaccine called H2NVAC in patients with a specific type of early, non-invasive breast cancer (DCIS) that has a protein called HER2. The goal is to see if the vaccine is safe, find the right dose, and learn if it can stimulate the patient's own immune system to recognize and potentially fight the cancer cells. Patients receive the vaccine shots before their standard surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST DUCTAL CARCINOMA IN SITU are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.